Journal
ANNALS OF ONCOLOGY
Volume 32, Issue 8, Pages 968-982Publisher
ELSEVIER
DOI: 10.1016/j.annonc.2021.03.197
Keywords
glioma; oncolytic virus; immunotherapy
Categories
Ask authors/readers for more resources
Gliomas are challenging to treat due to their resistance to conventional therapies, but immunotherapy, particularly oncolytic viruses, has shown promising results in recent studies. The review provides a comprehensive overview of completed human clinical investigations on oncolytic viruses for glioma treatment.
Gliomas remain one of the more frustrating targets for oncologic therapy. Glioma resistance to conventional therapeutics is a product of their immune-privileged milieu behind the blood-brain barrier, in addition to their suppressive effect on the immune response itself. Taking the lead from the growing success of immunotherapy for systemic cancers, such as lung cancer and melanoma, immunotherapeutics has emerged as a major player in the potential treatment of gliomas, with oncolytic viruses in particular showing significant promise as evidenced by the recent Breakthrough and Fast Tract Designations for PVSRIPO and DNX2401. This review serves as a useful and updated compendium of the completed human clinical investigations for several oncolytic viruses in the treatment of gliomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available